Cargando…
Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHOD...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118992/ https://www.ncbi.nlm.nih.gov/pubmed/29641738 http://dx.doi.org/10.20945/2359-3997000000025 |
_version_ | 1785028925450092544 |
---|---|
author | Súss, Shirlei Kugler Aiçar Mesa, Cleo Otaviano de Carvalho, Gisah Amaral Miasaki, Fabíola Yukiko Chaves, Carolina Perez Fuser, Dominique Cochat Corbo, Rossana Momesso, Denise Bulzico, Daniel A. Graf, Hans Vaisman, Fernanda |
author_facet | Súss, Shirlei Kugler Aiçar Mesa, Cleo Otaviano de Carvalho, Gisah Amaral Miasaki, Fabíola Yukiko Chaves, Carolina Perez Fuser, Dominique Cochat Corbo, Rossana Momesso, Denise Bulzico, Daniel A. Graf, Hans Vaisman, Fernanda |
author_sort | Súss, Shirlei Kugler Aiçar |
collection | PubMed |
description | OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHODS: A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. RESULTS: From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). CONCLUSIONS: Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes. |
format | Online Article Text |
id | pubmed-10118992 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-101189922023-04-22 Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy Súss, Shirlei Kugler Aiçar Mesa, Cleo Otaviano de Carvalho, Gisah Amaral Miasaki, Fabíola Yukiko Chaves, Carolina Perez Fuser, Dominique Cochat Corbo, Rossana Momesso, Denise Bulzico, Daniel A. Graf, Hans Vaisman, Fernanda Arch Endocrinol Metab Original Article OBJECTIVE: To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). SUBJECTS AND METHODS: A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. RESULTS: From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). CONCLUSIONS: Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes. Sociedade Brasileira de Endocrinologia e Metabologia 2018-03-23 /pmc/articles/PMC10118992/ /pubmed/29641738 http://dx.doi.org/10.20945/2359-3997000000025 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Súss, Shirlei Kugler Aiçar Mesa, Cleo Otaviano de Carvalho, Gisah Amaral Miasaki, Fabíola Yukiko Chaves, Carolina Perez Fuser, Dominique Cochat Corbo, Rossana Momesso, Denise Bulzico, Daniel A. Graf, Hans Vaisman, Fernanda Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title | Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_full | Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_fullStr | Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_full_unstemmed | Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_short | Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy |
title_sort | clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mci for ablation or without radioactive iodine therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118992/ https://www.ncbi.nlm.nih.gov/pubmed/29641738 http://dx.doi.org/10.20945/2359-3997000000025 |
work_keys_str_mv | AT sussshirleikugleraicar clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT mesacleootaviano clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT decarvalhogisahamaral clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT miasakifabiolayukiko clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT chavescarolinaperez clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT fuserdominiquecochat clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT corborossana clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT momessodenise clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT bulzicodaniela clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT grafhans clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy AT vaismanfernanda clinicaloutcomesoflowandintermediateriskdifferentiatedthyroidcancerpatientstreatedwith30mciforablationorwithoutradioactiveiodinetherapy |